RecruitingPhase 1Phase 2NCT07520006

Study of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies

An Open-label, Multicenter Phase 1b/2 Study to Evaluate the Safety and Efficacy of NX-5948 in Combination With Other Agents in Adults With B-cell Malignancies

Sponsor

Nurix Therapeutics, Inc.

Enrollment

150 participants

Start Date

Aug 1, 2026

Study Type

INTERVENTIONAL

Conditions

Chronic Lymphocytic Leukemia Small Lymphocytic Lymphoma B-cell Lymphoma

Summary

The study will evaluate NX-5948 (bexobrutideg) in combination with venetoclax with or without an anti-CD20 antibody (rituximab or obinutuzumab) in second-line or higher (2L+) relapsed/refractory (R/R) or first-line (1L) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL).

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called NX-5948, a drug called obinutuzumab, and others for people with b-cell lymphoma, chronic lymphocytic leukemia, and other related conditions. The study is currently recruiting participants at 6 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGNX-5948

Administered orally once daily as a capsule

DRUGvenetoclax

Administered orally once daily as a tablet per prescribing information

DRUGrituximab

Administered as an intravenous (IV) infusion per prescribing information

DRUGobinutuzumab

Administered as an IV infusion per prescribing information

Locations(6)

Rocky Mountain Cancer Centers

Aurora, Colorado, United States

University of Miami

Coral Gables, Florida, United States

Oncology Associates of Oregon

Eugene, Oregon, United States

UPMC Hillman Cancer Center

Pittsburgh, Pennsylvania, United States

SCRI Oncology Partners

Nashville, Tennessee, United States

Texas Oncology - Northeast

Tyler, Texas, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07520006

Related Trials

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study

NCT04269902631 locations

Natural History Study of Monoclonal B Cell Lymphocytosis (MBL), Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL), Lymphoplasmacytic Lymphoma (LPL)/Waldenstrom Macroglobulinemia (WM), and Splenic Marginal Zone Lymphoma (SMZL)

NCT009235071 location

A Study of LP-168 in Participants With Relapse or Refractory B-Cell Lymphoma

NCT049936903 locations

A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors

NCT06846671124 locations

A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)

NCT06136559200 locations